Completed OBSERVATIONAL NCT04301661

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

Sponsor: University of Colorado, Denver

Interventions Abacavir/lamivudine Blood collection Switch Tenofovir alafenamide/emtricitabine

Updated 9 times since 2020 Last updated: Jan 5, 2023 Started: Mar 6, 2020 Primary completion: Dec 17, 2021 Completion: Dec 17, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates HIV-1-infection and is currently completed. University of Colorado, Denver leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Feb 2023 — Jul 2024 [monthly]

Completed

Status: Recruiting → Completed
Dec 2021 — Feb 2023 [monthly]

Recruiting
Oct 2021 — Dec 2021 [monthly]

Recruiting

▶ Show 4 earlier versions

Jan 2021 — Oct 2021 [monthly]

Recruiting
Nov 2020 — Jan 2021 [monthly]

Recruiting
Sep 2020 — Nov 2020 [monthly]

Recruiting
Apr 2020 — Sep 2020 [monthly]

Recruiting

First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Colorado, Denver

Data source: University of Colorado, Denver

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aurora, United States